Maximal caution and a shared decision-making approach is required for women using Aromatase Inhibitors (AIs) for breast cancer risk reduction when choosing treatments for GSM.<h4>Conclusions</h4>Treating GSM improves vaginal, sexual and urinary outcomes and quality of life of women. The gene discussed is CYP19A1; the disease is breast cancer.